Protalix BioTherapeutics Inc (DE)

Financials

総資産 67.93 M73.67 M55.79 M84.43 M73.42 M82.35 M 負債合計 94.97 M79.7 M66.43 M50.87 M30.21 M34.12 M 純資産合計 -27.04 M-6.04 M-10.64 M33.57 M43.21 M48.23 M 負債および純資産合計 67.93 M73.67 M55.79 M84.43 M73.42 M82.35 M 有利子負債合計 —27.89 M28.19 M——— 純負債 —-11.1 M11.08 M———

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

PLX

Financials

Protalix BioTherapeutics Inc (DE)

ニュース

Protalix: Elfabrio Struggles Against Oral Competition (NYSE:PLX)

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance (NYSE:PLX)

Brazil judge overrules decisions suspending changes to meal voucher system

A March Decision That Could Change Protalix’s Outlook (NYSE:PLX)

Pluxee社とEdenred社、好調な業績と見通しを受け株価急騰

Pluxee, Edenred shares jump after upbeat results and outlook

Pluxee 2026年度第1四半期：ブラジルの課題の中でも9%の収益成長

Pluxee posts 9% growth in Q1; confirms 2026 outlook despite Brazil headwinds

プロタリックス、制御不能な痛風治療に焦点を当てた2026年戦略を概説

Tuesday’s Insider Activity: Key Execs Make Notable Trades

プロタリックス・バイオセラピューティクスのCEOバシャン・ドロール氏が10万ドル超の株式を購入

BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN)